S.Biomedics에스바이오메딕스
304360 · KOSDAQ · ₩304360 · 에스바이오메딕스
- Market cap
- ₩252B
- Enterprise value
- ₩234B
- P/E
- —
- P/B
- 8.3×
- Dividend yield
- 0.0%
- ROE
- −39.7%
- Net margin
- −73.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.6% from the high
₩13,910Today: ₩20,050 – ₩20,750₩42,600
Returns
- 1W−6.0%
- 1M+0.2%
- 3M+26.3%
- 6M−41.6%
- YTD−46.8%
- 1Y−18.5%
- Volume today
- 8,065
- 0.3× the 20-day average
- Traded today
- ₩163M
- Listed shares
- 12,481,128
- EPS (12 months)
- −₩966
- Earnings yield −4.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- MomentumFlat0.5% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
S.Biomedics stock overview
S.Biomedics (에스바이오메딕스, KRX: 304360) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech venture founded in 2004 that researches, develops, manufactures and sells stem cell-based medicines, focusing on regenerative medicine and cell therapy products for hard-to-treat, rare and chronic diseases. Its shares closed at ₩20,200 on Oct 27, 2026, up 0.75% on the day, giving it a market value of ₩252B.
Key facts
- Market cap
- ₩252B
- Sector
- Biotech & Pharma
- Latest price change
- +0.75%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean biotech venture founded in 2004 that researches, develops, manufactures and sells stem cell-based medicines, focusing on regenerative medicine and cell therapy products for hard-to-treat, rare and chronic diseases.
Quick answers about S.Biomedics
- What does S.Biomedics do?
- The company is a Korean biotech venture founded in 2004 that researches, develops, manufactures and sells stem cell-based medicines, focusing on regenerative medicine and cell therapy products for hard-to-treat, rare and chronic diseases. Through its subsidiaries, S-Biomedics (stem cell therapeutics) and S-Tpharm (medical devices and cosmetics), it also makes and sells fillers and fibroblast culture cosmetics, with business centered in South Korea.
- What is the market cap of S.Biomedics?
- The market capitalisation of S.Biomedics was ₩252B at the close on Oct 27, 2026.
- Who are the largest shareholders of S.Biomedics?
- According to the latest official filings, the largest reported holders are KANG SAEIL (16.50%, as of Aug 31, 2026); Tiger Asset Management Discretionary Investment (6.85%, as of Apr 22, 2026); Bynex (4.93%, as of Dec 10, 2024).
- When is the next earnings report from S.Biomedics?
- Korean companies rarely announce results dates in advance. Based on when S.Biomedics filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
The company is a Korean biotech venture founded in 2004 that researches, develops, manufactures and sells stem cell-based medicines, focusing on regenerative medicine and cell therapy products for hard-to-treat, rare and chronic diseases. Through its subsidiaries, S-Biomedics (stem cell therapeutics) and S-Tpharm (medical devices and cosmetics), it also makes and sells fillers and fibroblast culture cosmetics, with business centered in South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 에스바이오메딕스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 강세일
- Founded
- Aug 2003
- Listed
- May 2023
- Listed shares
- 12,481,128
- Fiscal year ends
- Month 12
- Website
- www.sbiomedics.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Insider shareholding reportAug 31, 2026
- 5%+ holding reportAug 25, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Adjustment of Conversion Price (5th Series)Aug 13, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity (5th Round)Aug 13, 2026
Titles in Korean until English translations are added.
Also known as: S.Biomedics / 에스바이오메딕스 / 304360 / KRX:304360
Source: KRX statistical information